Mishani E - Search Results

1

Tyrphostins and other tyrosine kinase inhibitors.

Levitzki A, Mishani E. Levitzki A, et al. Among authors: mishani e. Annu Rev Biochem. 2006;75:93-109. doi: 10.1146/annurev.biochem.75.103004.142657. Annu Rev Biochem. 2006. PMID: 16756486 Review.

2

Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.

Ortu G, Ben-David I, Rozen Y, Freedman NM, Chisin R, Levitzki A, Mishani E. Ortu G, et al. Among authors: mishani e. Int J Cancer. 2002 Oct 1;101(4):360-70. doi: 10.1002/ijc.10619. Int J Cancer. 2002. PMID: 12209961

3

Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer.

Shaul M, Abourbeh G, Jacobson O, Rozen Y, Laky D, Levitzki A, Mishani E. Shaul M, et al. Among authors: mishani e. Bioorg Med Chem. 2004 Jul 1;12(13):3421-9. doi: 10.1016/j.bmc.2004.04.044. Bioorg Med Chem. 2004. PMID: 15186828

4

High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.

Mishani E, Abourbeh G, Jacobson O, Dissoki S, Ben Daniel R, Rozen Y, Shaul M, Levitzki A. Mishani E, et al. J Med Chem. 2005 Aug 11;48(16):5337-48. doi: 10.1021/jm0580196. J Med Chem. 2005. PMID: 16078851

5

The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor.

Dissoki S, Aviv Y, Laky D, Abourbeh G, Levitzki A, Mishani E. Dissoki S, et al. Among authors: mishani e. Appl Radiat Isot. 2007 Oct;65(10):1140-51. doi: 10.1016/j.apradiso.2007.04.014. Epub 2007 May 8. Appl Radiat Isot. 2007. PMID: 17574425

6

Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.

Bonasera TA, Ortu G, Rozen Y, Krais R, Freedman NM, Chisin R, Gazit A, Levitzki A, Mishani E. Bonasera TA, et al. Among authors: mishani e. Nucl Med Biol. 2001 May;28(4):359-74. doi: 10.1016/s0969-8051(01)00200-1. Nucl Med Biol. 2001. PMID: 11395308

7

Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors.

Mishani E, Abourbeh G, Rozen Y, Jacobson O, Laky D, Ben David I, Levitzki A, Shaul M. Mishani E, et al. Nucl Med Biol. 2004 May;31(4):469-76. doi: 10.1016/j.nucmedbio.2003.12.005. Nucl Med Biol. 2004. PMID: 15093817

8

Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors.

Abourbeh G, Dissoki S, Jacobson O, Litchi A, Ben Daniel R, Laki D, Levitzki A, Mishani E. Abourbeh G, et al. Among authors: mishani e. Nucl Med Biol. 2007 Jan;34(1):55-70. doi: 10.1016/j.nucmedbio.2006.10.012. Nucl Med Biol. 2007. PMID: 17210462

9

PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors.

Abourbeh G, Shir A, Mishani E, Ogris M, Rödl W, Wagner E, Levitzki A. Abourbeh G, et al. Among authors: mishani e. IUBMB Life. 2012 Apr;64(4):324-30. doi: 10.1002/iub.1002. Epub 2012 Feb 23. IUBMB Life. 2012. PMID: 22362419 Free PMC article.

10

Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.

Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Mishani E, et al. Curr Pharm Des. 2008;14(28):2983-98. doi: 10.2174/138161208786404326. Curr Pharm Des. 2008. PMID: 18991714 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters